– CANADA, Calgary – Willow Biosciences Inc. (TSX: WLLW | OTC: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced the appointments of current COO, Dr. Chris Savile as President and CEO, and of founder and Board member, Trevor Peters, as Chairman, effective March 28, 2023, concurrently with the retirement of Dr. Peter Seufer-Wasserthal as CEO. Dr. Seufer-Wasserthal will continue to be a Director of the Company.
Additionally, Raffi Asadorian will join the Board of Directors as an independent director at the AGM on May 12, 2023.
About Raffi Asadorian
Mr. Asadorian has been CFO of AcelRx Pharmaceuticals, a NASDAQ-listed, commercial-stage specialty pharmaceutical company since August 2017. Mr. Asadorian has over 30 years of experience in finance, including 15 years experience as a CFO with publicly listed and private equity-owned biotech and life sciences companies including Amyris and Barr Pharmaceuticals. Before that, Mr. Asadorian was a Partner in the Transaction Services Group of PwC, LLP in New York.
Mr. Asadorian holds an MBA in Finance from the University of Manchester and a B. Sc., Business Administration in Accounting from Xavier University in Cincinnati. Mr. Asadorian is a Certified Public Accountant (inactive, Ohio).
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage, and personal care markets. Willow’s FutureGrown biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information: https://willowbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.